Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jun 7;21(1):134.
doi: 10.1186/s13054-017-1712-3.

Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study

Yoshihiko Nakamura  1 , Taisuke Kitamura  1 , Fumiaki Kiyomi  2 , Mineji Hayakawa  3 , Kota Hoshino  1 , Yasumasa Kawano  1 , Reiko Yamasaki  1 , Takeshi Nishida  1 , Mariko Mizunuma  1 , Hiroyasu Ishikura  4 ; Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group
Collaborators, Affiliations
Observational Study

Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study

Yoshihiko Nakamura et al. Crit Care. .

Abstract

Background: The purpose of this study was to investigate whether polymyxin B hemoperfusion (PMX-HP) improves the survival of patients with septic shock.

Methods: This was a retrospective, multicenter study conducted on patients treated during a 3-year period. We performed propensity-score analyses of the Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study database. The study included data on 1723 patients with septic shock aged 16 years or older. Furthermore, we divided patients into to PMX-HP- and non-PMX-HP-treated groups. The primary endpoint was all-cause hospital mortality; secondary endpoints included intensive care unit (ICU) mortality and number of ICU-free days (ICUFDs) in the first 28 days.

Results: Of 1,723 eligible patients, 522 had received PMX-HP. Propensity score matching created 262 matched pairs (i.e., 262 patients in each of the non-PMX-HP and PMX-HP groups). The proportion of all-cause hospital mortality was significantly lower in the PMX-HP group than in the non-PMX-HP group (32.8% vs. 41.2%; odds ratio (OR): 0.681; 95% confidence interval (CI): 0.470-0.987; P = 0.042). The number of ICUFD in the first 28 days was significantly higher in the PMX-HP group than in the non-PMX-HP group (18 (0-22) vs. 14 (0-22) days, respectively; P = 0.045). On the other hand, there was no significant difference in ICU mortality between the two groups (21.8% vs. 24.4%; OR: 0.844; CI: 0.548-1.300; P = 0.443).

Conclusions: Our results strongly suggest that PMX-HP reduces all-cause hospital mortality and length of ICU stay in patients with septic shock.

Keywords: Intensive care unit-free days; Mortality; Polymyxin B hemoperfusion; Propensity score matching; Septic shock.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient selection schema. ICU intensive care unit, PMX-HP polymyxin B hemoperfusion, PT-INR prothrombin time-international normalized ratio, SOFA Sequential Organ Failure Assessment
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10. doi: 10.1097/00003246-200107000-00002. - DOI - PubMed
    1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637. doi: 10.1097/CCM.0b013e31827e83af. - DOI - PubMed
    1. da Silva AM T, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med. 1993;328:1457–60. doi: 10.1056/NEJM199305203282005. - DOI - PubMed
    1. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520–6. - PubMed
    1. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584–9. doi: 10.1086/315093. - DOI - PubMed

Publication types

MeSH terms